The Clues

Four ways the stem hands it to you

Any one of these in a vignette is enough. Two of them is the answer. Stop reading at the second clue and pick Parkinson.

Clue 01

TRAP cluster

Tremor at rest, Rigidity (cogwheel), Akinesia or bradykinesia, Postural instability with shuffling gait. Three of the four is the floor for a clinical diagnosis.

Clue 02

Pillrolling at rest

A 4 to 6 Hz thumb-against-finger tremor that shows up when the hand sits still and improves the second the patient grabs for something. Asymmetric. Worse on one side first.

Clue 03

Lewy bodies on path

Round, eosinophilic, cytoplasmic inclusions of aggregated alpha-synuclein inside surviving neurons of the substantia nigra. Pathognomonic for idiopathic Parkinson.

Clue 04

Levodopa walks them back

The motor signs improve dramatically on levodopa. If a patient's symptoms do not budge on a real dose, the diagnosis was probably not Parkinson to begin with.

The Mnemonic

TRAP, one letter at a time

Tap each letter. The cluster locks in faster when you say it out loud.

T · Tremor at rest

Pillrolling, 4 to 6 Hz, asymmetric, present when the limb is supported and at rest. Quiets the second the patient reaches for something. Goes away in sleep. Stem giveaway: "rolling a pill between thumb and index finger" or "tremor disappears when she reaches for the cup."

The Anatomy

Substantia nigra, healthy vs dying

Axial cross-section through the midbrain at the level of the superior colliculi. Toggle the state.

Healthy. The substantia nigra pars compacta is jet black on a fresh midbrain section because its dopaminergic neurons are packed with neuromelanin. Two crescent strips sit on top of the cerebral peduncles, projecting forward into the striatum.

The Pathology

Lewy body, photo and schematic

Real H&E on the left so you know what it looks like under the scope. Schematic on the right so you know what is happening inside.

Real photo · H&E

Lewy body in the substantia nigra, H&E stain

Substantia nigra neuron with a round, eosinophilic Lewy body in the cytoplasm. Public domain · Wikimedia Commons.

Lewy body within a neuron

What you are looking at: aggregated alpha-synuclein clumps in the cytoplasm of a surviving substantia nigra neuron. On H&E it reads as a round, pink, eosinophilic ball with a pale halo, sitting beside a pushed-aside nucleus. Idiopathic Parkinson disease cannot leave without depositing one of these.

The synucleinopathies family: alpha-synuclein is THE protein that links three diseases. Parkinson disease (Lewy bodies in substantia nigra), Lewy body dementia (Lewy bodies in cortex too, which is why the cognitive piece arrives early), and multiple system atrophy (alpha-synuclein in glial cells instead of neurons, with early autonomic failure). Same protein, different real estate, three different clinical pictures.

The Cascade

Alpha-synuclein, monomer to Lewy body

Five stages from a normal folded protein to the toxic inclusion that kills the neuron. Tap a stage.

Monomer. The native folded form. Alpha-synuclein normally lives at the presynaptic terminal of healthy neurons, where it helps recycle synaptic vesicles. In this state it is harmless. Then a hit (genetics, oxidative stress, a misfolding seed) flips one molecule into a wrong shape, and the cascade begins. Why it matters: the protein that becomes the Lewy body starts as a normal, useful piece of the synapse. Parkinson is what happens when housekeeping breaks.

The Gait

Upright vs stooped, side by side

Two figures, same scale. The Parkinson silhouette is what a clinician sees walking down the hallway.

Normal

Head over hips, trunk upright
Arms swing through full stride, opposite to leg
Heel strike with regular step length
Smooth turn on a single pivot

Parkinson

Stooped trunk, head pulled forward
Arms flexed at elbows, decreased or absent arm swing
Small shuffling steps, festinating (speeding up)
Turns in many tiny steps (en bloc), retropulsion on pull test

The Move

Treatment ladder

Climb from the cleanest motor win to the heavier hardware. Tap a rung.

Levodopa is the dopamine precursor that actually crosses the blood-brain barrier. Dopamine itself cannot. So you give the precursor and let the brain finish the synthesis on the inside.

Why carbidopa is bolted on: peripheral DOPA decarboxylase (in the gut wall and bloodstream) will convert most of the levodopa to dopamine BEFORE it ever reaches the brain. That peripheral dopamine causes nausea, vomiting, orthostatic hypotension, and arrhythmias, and it cannot cross the blood-brain barrier to help the patient. Carbidopa inhibits peripheral DOPA decarboxylase, and crucially carbidopa itself does not cross the BBB. Net result: more levodopa survives the trip and reaches the brain, fewer peripheral side effects, lower total dose needed.

Long-term levodopa side effects: after roughly five years, patients develop on-off motor fluctuations (the drug works, then suddenly does not) and peak-dose dyskinesias (involuntary writhing movements; this is the patient who looks "treated" because they are moving constantly). Late-stage levodopa can also cause anxiety, agitation, and psychosis with visual hallucinations. The drug still works; the therapeutic window just narrows over time.

Pearl: if a patient with suspected Parkinson does not improve on an adequate levodopa trial, reconsider the diagnosis. Atypical parkinsonism barely budges.

Examples: pramipexole, ropinirole, rotigotine (patch). Directly stimulate the postsynaptic D2 receptors in the striatum, skipping the substantia nigra entirely.

Often started first in patients under 65 to delay the levodopa clock, since levodopa-related dyskinesias track with cumulative exposure. Watch for impulse-control behaviors (gambling, hypersexuality, binge eating), daytime somnolence, and orthostatic hypotension.

Pearl: the impulse-control side effect is the discriminator in board questions; a Parkinson patient with new compulsive gambling on a new drug is almost always on a dopamine agonist.

Examples: selegiline, rasagiline, safinamide. Inhibit MAO-B inside the synaptic cleft so the dopamine that is left lingers longer.

Useful as monotherapy in early disease, or as an add-on when levodopa starts wearing off between doses. Selegiline gets metabolized partly to amphetamine, so insomnia is real.

Pearl: combining any MAO-B inhibitor with an SSRI, SNRI, or meperidine risks serotonin syndrome. Screen the med list.

Examples: entacapone, opicapone, tolcapone. Block the COMT enzyme that converts levodopa to 3-O-methyldopa in the periphery, so more levodopa reaches the brain on each dose.

Always used as an add-on to levodopa, not alone. Entacapone is the standard pick; tolcapone is reserved because of rare fatal hepatotoxicity (requires LFT monitoring). Common side effect: orange-tinted urine, which is harmless.

Pearl: COMT inhibitors smooth out end-of-dose wearing-off. They do not work without levodopa already on board.

Originally an antiviral. Modest direct anti-Parkinson effect plus a distinct second life as the go-to drug for levodopa-induced dyskinesias, where its NMDA antagonism reduces the involuntary movements without sacrificing levodopa benefit.

Side effects: livedo reticularis (mottled, lacy rash on legs), ankle edema, hallucinations in older patients.

Pearl: if a board stem mentions livedo reticularis in a Parkinson patient, the drug is amantadine.

Examples: benztropine, trihexyphenidyl. Block muscarinic receptors in the striatum to rebalance the dopamine-acetylcholine seesaw that tips toward acetylcholine when nigral dopamine drops.

Best at tremor specifically, weak on bradykinesia and rigidity. Avoided in older patients because of confusion, urinary retention, constipation, blurred vision, dry mouth, and falls.

Pearl: the niche is a younger Parkinson patient whose dominant complaint is tremor. Old patient with mild cognitive impairment? Stay away.

Electrodes implanted into the subthalamic nucleus (STN) or the globus pallidus interna (GPi), attached to a chest-wall pulse generator. High-frequency stimulation disrupts the abnormal basal-ganglia output that drives Parkinson motor symptoms.

Reserved for patients with disabling motor symptoms or dyskinesias despite optimized medical therapy, who still respond to levodopa (i.e., the diagnosis is solid), with intact cognition and reasonable surgical candidacy.

Pearl: DBS improves the same symptoms that levodopa improves. If levodopa never helped, DBS will not either.

Drug Class · Deeper Cut

Dopamine agonists, the parallel option

Bypass the dying neurons. Hit the receptor directly. Used for Parkinson AND restless leg syndrome, with a trap built into long-term use.

Class · D2 receptor agonist Direct stim

Pramipexole Oral · first-line in younger PD and RLS

Ropinirole Oral · PD and RLS, similar profile

Rotigotine Patch · transdermal 24-hour delivery

Bromocriptine Older ergot derivative

Cabergoline Long-acting ergot derivative

Apomorphine Subcutaneous rescue for off episodes

What they do: directly stimulate postsynaptic D2 receptors in the striatum. They do not need the substantia nigra to convert anything. The dying neurons can stop showing up to work; the receptor still gets the signal.

When to pick them: first-line alternative in Parkinson patients under 65 to delay starting levodopa, since levodopa-related dyskinesias track with cumulative levodopa exposure. Use the agonist now, save the levodopa years for later. Also first-line for restless leg syndrome, where the same dopaminergic signaling deficit is at play in a different circuit.

The augmentation trap (especially with pramipexole in RLS): over months to years, symptoms creep earlier in the day, become more intense, and spread from legs to arms and trunk. The drug is making the disease worse. Mechanism: chronic D2 stimulation eventually drives D1 receptor activity, which paradoxically worsens symptoms. The fix is to switch to gabapentin or pregabalin, alpha-2-delta calcium channel ligands that quiet the circuit without touching dopamine.

Other side effects to watch: impulse-control behaviors (gambling, hypersexuality, binge eating, compulsive shopping), daytime somnolence with sleep attacks, orthostatic hypotension, peripheral edema, hallucinations in older patients.

Pearl: a Parkinson or RLS patient who started a new dopamine agonist and developed compulsive gambling on top of it is not a coincidence. The drug is doing it. Reduce the dose or switch class. See restless leg syndrome >

Drug Class · Deeper Cut

COMT inhibitors, the levodopa extender

Block the second peripheral leak. More levodopa to brain, longer dose half-life, smoother motor day.

Class · COMT inhibitor "Al CAPONE COMiT crimes"

Entacapone Standard pick · given with each levodopa dose

Tolcapone Reserved · rare fatal hepatotoxicity, monitor LFTs

Opicapone Once-daily dosing add-on

"Capone" cue enta-CAPONE, tol-CAPONE = COMT

What COMT does normally: Catechol-O-Methyltransferase is an enzyme that breaks down catecholamines. In the periphery it methylates levodopa to 3-O-methyldopa (which the brain cannot use). In the synapse it breaks down dopamine that has already done its job. Both jobs shorten how long any given levodopa dose works.

What inhibitors do: block COMT so more levodopa survives the trip to the brain on each dose, and the dopamine produced inside the synapse hangs around longer before being cleared. The result is a smoother motor day with fewer end-of-dose "wearing off" troughs.

How they are used: always as an add-on to levodopa+carbidopa, never alone. Without levodopa on board there is nothing for COMT to act on, so blocking COMT does nothing. Common harmless side effect: orange-tinted urine from the drug itself.

Mnemonic: "Al CAPONE COMiT crimes." Both entaCAPONE and tolCAPONE end in CAPONE; the crime they commit is blocking COMT.

Pearl: COMT inhibitors smooth out wearing-off, they do not work as monotherapy. Tolcapone is the one to memorize for rare fatal hepatotoxicity (LFT monitoring required); entacapone is the safe everyday pick.

The Circuit

Direct vs indirect pathway

Two basal ganglia loops, opposite jobs, both run on dopamine. Toggle healthy vs Parkinson to see why movement collapses.

Direct · D1 · "GO"

Cortex fires the striatum. The striatum (GABA) inhibits the GPi. GPi normally brakes the thalamus, so quieting GPi releases the thalamus, which fires the cortex back. Net: more movement.

Indirect · D2 · "STOP"

Cortex fires the striatum, which inhibits the GPe. With the GPe quieted, the STN is unleashed (glutamate) and drives GPi harder. GPi brakes the thalamus more. Net: less movement.

Healthy. Substantia nigra dopamine stimulates D1 (turns the direct GO pathway up) and blocks D2 (turns the indirect STOP pathway down). Both pushes net to more movement. The two loops stay balanced, the patient walks normally.

The Hardware

Deep brain stimulation (DBS)

Electrodes into the basal ganglia. For patients who still respond to levodopa but have stopped getting smooth days from it.

When to consider DBS: medically refractory motor fluctuations or dyskinesias, in a patient who still responds to levodopa (proves the diagnosis is real and the dopamine receptors still work), with intact cognition and a reasonable surgical risk profile. DBS does not cure Parkinson and does not stop progression. It smooths the on-off swings and lets the team lower the levodopa dose. Rule of thumb: DBS improves the symptoms levodopa already improves. If levodopa never helped, DBS will not either.

Test Yourself

Ten vignettes, all original

No question is lifted from any qbank. Pure board logic, written for this page.

Ten questions. Read the stem, tap your pick. Each wrong choice gets its own kill-shot rule so you walk away smarter than you came.

Study maps

Parkinson Disease